Overview

Safety and Tolerability Study of Farnesyl Protein Transferase Inhibitor in Combination With Gemcitabine and Cisplatin in Advanced Cancer (Study P01499)(TERMINATED)

Status:
Terminated
Trial end date:
2004-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and tolerability of an oral Farnesyl Protein Transferase Inhibitor (SCH 66336) when given in combination with Gemcitabine and Cisplatin in patients with advanced cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.